AUS
NZ
UK
CA
USA
IND
Kyverna Therapeutics, Inc. announced a new Clinical and Commercial Supply Agreement with ElevateBio Basecamp, Inc., effective July 23, 2026, superseding their previous development and manufacturing services contract. This agreement creates a formalized framework for manufacturing and supplying mivocabtagene autoleucel (miv-cel), Kyverna's lead product candidate, with an initial term of five years and automatic renewal options. It includes minimum purchase commitments and pricing adjustments linked to inflation metrics, positioning Kyverna for scaled production as it progresses miv-cel toward potential regulatory approval.
Key Points
- NASDAQ: KYTX
- Kyverna replaced its prior agreement with ElevateBio, initially signed on July 22, 2023, with a new Clinical and Commercial Supply Agreement effective July 23, 2026
- The agreement features a five-year initial term with automatic one-year renewal periods unless terminated by either party with prior notice or due to an uncured material breach
- Kyverna is obligated to order minimum quantities of miv-cel in designated calendar years and upon regulatory approval; pricing is subject to annual adjustments based on the Producer Price Index for Pharmaceutical Preparation Manufacturing
From Development Agreement to Expanded Manufacturing Partnership
Kyverna Therapeutics has restructured its manufacturing collaboration with ElevateBio by replacing the Development and Manufacturing Services Agreement dated July 22, 2023 (amended July 24, 2023), with a comprehensive Clinical and Commercial Supply Agreement. This shift marks Kyverna's progression from development-stage manufacturing to a framework supporting both clinical and commercial-scale production of miv-cel. The previous agreement lacked commercial supply provisions now embedded in the new contract.
This transition indicates Kyverna’s advancement in miv-cel’s development, preparing for potential regulatory approval and associated manufacturing demands. ElevateBio remains the exclusive manufacturing partner, reflecting confidence in their ability to scale production to meet future needs.
Five-Year Term with Automatic Renewal and Termination Options
The agreement’s initial five-year term aligns with typical timelines for clinical development, regulatory review, and early commercial launch of biotech products. This duration offers medium-term planning certainty as miv-cel progresses through clinical trials and potential FDA approval.
Automatic renewal for successive one-year terms applies unless either party provides advance notice of non-renewal or terminates due to an uncured material breach. This structure balances continuity of supply with flexibility for both Kyverna and ElevateBio to reassess the partnership post initial term. The material breach clause ensures contractual remedies if obligations are unmet.
Minimum Purchase Obligations Linked to Regulatory Milestones
Kyverna commits to ordering minimum quantities of miv-cel in specified calendar years and following regulatory approval by the FDA or other authorities. Specific minimum volumes and timing details are confidential and will be disclosed under confidential treatment in the company's next quarterly report. This arrangement guarantees predictable demand for ElevateBio while preserving Kyverna’s commercial flexibility based on regulatory outcomes.
Such milestone-based purchase commitments are standard in cell therapy manufacturing agreements, aligning incentives by tying production volumes to regulatory progress and market readiness.
Pricing Mechanism with Inflation-Based Annual Adjustments
The contract includes a pricing structure where product prices and ElevateBio’s service fees adjust annually based on inflation, capped according to the Producer Price Index for Pharmaceutical Preparation Manufacturing. This ensures transparent, predictable cost increases aligned with pharmaceutical manufacturing inflation, avoiding arbitrary price hikes or frequent renegotiations.
Detailed pricing and fees will be specified in statements of work executed under the agreement, a common practice in complex manufacturing contracts to separate overarching terms from project-specific details.
Robust Quality, Testing, and Confidentiality Measures
The agreement incorporates standard acceptance, warranty, quality control, testing, inspection, audit, information access, and confidentiality provisions essential for regulated pharmaceutical manufacturing. These ensure batch consistency, regulatory compliance, and patient safety for miv-cel.
Acceptance criteria define standards for batch approval before Kyverna takes possession. Warranty and quality clauses protect against manufacturing defects, while audit rights enable verification of ElevateBio’s compliance. Confidentiality safeguards proprietary information and manufacturing processes. Kyverna plans to seek confidential treatment for sensitive agreement terms in its upcoming quarterly filing.
Inclusion in Upcoming Quarterly Report and Disclosure Timing
The full Clinical and Commercial Supply Agreement will be filed in Kyverna’s Form 10-Q for the fiscal quarter ending September 30, 2026, approximately two months post-execution. This filing will provide investors access to detailed pricing, minimum purchase commitments, and technical terms, subject to any SEC-approved redactions.
Confidential treatment requests reflect industry norms to protect competitive commercial and manufacturing details while maintaining transparency on key partnership terms.
Joint Press Release and Regulatory Filing Details
On July 27, 2026, Kyverna Therapeutics and ElevateBio jointly announced the Clinical and Commercial Supply Agreement via a press release, which was furnished to the SEC as Exhibit 99.1 and incorporated by reference in the current report. This disclosure confirms the significance of the partnership and its impact on Kyverna’s manufacturing strategy.
The filing clarifies that the press release is not considered "filed" under Section 18 of the Securities Exchange Act, limiting liability for forward-looking statements but not diminishing the announcement’s importance.
Emerging Growth Company Status and Accounting Compliance
Kyverna is designated as an emerging growth company under Securities Act Rule 405 and Exchange Act Rule 12b-2. The company has opted not to use the extended transition period for new or revised accounting standards, indicating it will adopt updated financial reporting requirements concurrently with larger public companies.
This status affects disclosure obligations and may change as Kyverna’s revenue and market capitalization grow, potentially impacting future reporting requirements.
Strategic Manufacturing Partnership Supporting Cell Therapy Commercialization
The Clinical and Commercial Supply Agreement with ElevateBio is a vital element of Kyverna’s plan to commercialize mivocabtagene autoleucel. Cell therapy manufacturing demands specialized expertise and infrastructure for processes such as cell isolation, expansion, transduction, quality control, and cryopreservation.
By securing a five-year manufacturing partnership with defined minimum purchase commitments and inflation-adjusted pricing, Kyverna ensures a stable production foundation. ElevateBio’s exclusive role enables Kyverna to concentrate on clinical development and regulatory efforts while leveraging ElevateBio’s manufacturing capabilities.
The inclusion of clinical and commercial supply provisions reflects the realistic potential for miv-cel to achieve regulatory approval within the agreement term. Minimum purchase commitments linked to approval mitigate ElevateBio’s investment risk and guarantee Kyverna access to manufacturing capacity upon product approval.
